Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 13/20 | 0.43 |
| ▸ | CNR1 | P21554 | 11/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | RBP1 | P09455 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29446963 | 1.00 | GPR55 (0.44) | GPR55CNR2CNR1CYP3A4ACHE | |
| SCHEMBL16010483 | 0.98 | GPR55 (0.45) | GPR55CNR2CNR1CYP3A4ACHE | |
| SCHEMBL16010045 | 0.90 | GPR55 (0.47) | GPR55CNR2CNR1CYP3A4ACHE | |
| SCHEMBL3133781 | 0.90 | CHRM1 (0.39) | GPR55CNR2CNR1CYP3A4PTPN1 | |
| SCHEMBL16018021 | 0.88 | CHRM1 (0.41) | GPR55CNR2CNR1CYP3A4ACHE | |
| Cyclomenol SCHEMBL2109474 | 0.85 | CNR1 (0.43) | CNR2CNR1ACHECHRM1TBXA2R | |
| SCHEMBL11701041 | 0.82 | CNR1 (0.41) | CNR2CNR1ACHECHRM1TBXA2R | |
| SCHEMBL28155053 | 0.81 | CHRM1 (0.36) | GPR55CNR2CNR1CYP3A4PTPN1 | |
| SCHEMBL16018020 | 0.81 | CHRM1 (0.36) | GPR55CNR2CNR1CYP3A4PTPN1 | |
| SCHEMBL16018035 | 0.79 | CYP3A4 (0.44) | GPR55CYP3A4ACHEPTPN1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622861-B2 | Stable wash composition | CONOPCO, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12409117-B2 | Wash composition substantially free of oil | CONOPCO, INC. (US) | 2025-09-09 | — | — | US | claimed |
| US-20250205130-A1 | Hydratable Concentrate Composition and Sulfate free Wash Composition | CONOPCO, INC., D/B/A UNILEVER (US) | 2025-06-26 | — | — | US | claimed |
| US-20230398050-A1 | STABLE WASH COMPOSITION | CONOPCO, INC., D/B/A UNILEVER (US) | 2023-12-14 | — | — | US | claimed |
| CN-113557002-B | Multiple emulsions comprising oil continuous nanoemulsions and methods of using the same | 联合利华知识产权控股有限公司 | 2023-11-24 | — | — | CN | claimed |
| US-20230049117-A1 | HYDRATABLE CONCENTRATED SURFACTANT COMPOSITION | CONOPCO, INC., D/B/A UNILEVER (US) | 2023-02-16 | — | — | US | claimed |
| EP-3946221-B1 | MULTIPLE EMULSION COMPRISING AN OIL CONTINUOUS NANOEMULSION AND A METHOD FOR USING THE SAME | UNILEVER GLOBAL IP LTD (GB) | 2022-09-28 | — | — | EP | claimed |
| US-20220151886-A1 | MULTIPLE EMULSION COMPRISING AN OIL CONTINUOUS NANOEMULSION AND A METHOD FOR USING THE SAME | CONOPCO, INC., D/B/A UNILEVER (US) | 2022-05-19 | — | — | US | claimed |
| EP-3946221-A1 | MULTIPLE EMULSION COMPRISING AN OIL CONTINUOUS NANOEMULSION AND A METHOD FOR USING THE SAME | UNILEVER GLOBAL IP LIMITED (GB) | 2022-02-09 | — | — | EP | claimed |
| CN-113557002-A | Multiple emulsions comprising oil continuous nanoemulsions and methods of using the same | 联合利华知识产权控股有限公司 | 2021-10-26 | — | — | CN | claimed |
| US-20210220243-A1 | Hydratable Concentrated Surfactant Composition | CONOPCO, INC., D/B/A UNILEVER (US) | 2021-07-22 | — | — | US | claimed |
| WO-2020200979-A1 | MULTIPLE EMULSION COMPRISING AN OIL CONTINUOUS NANOEMULSION AND A METHOD FOR USING THE SAME | UNILEVER PLC (GB) | 2020-10-08 | — | — | WO | claimed |
| EP-3651728-A1 | FREEZE DRIED ACTIVE COMPOSITION AND A SYSTEM FOR USING THE SAME | Unilever PLC (GB) | 2020-05-20 | — | — | EP | claimed |
| CN-110913829-A | Freeze-dried active compositions and systems using same | 荷兰联合利华有限公司 | 2020-03-24 | — | — | CN | claimed |
| WO-2019011620-A1 | FREEZE DRIED ACTIVE COMPOSITION AND A SYSTEM FOR USING THE SAME | UNILEVER PLC (GB) | 2019-01-17 | — | — | WO | claimed |
| US-20260132356-A1 | MILD WASH COMPOSITION WITH BIODEGRADABLE THICKENER AND ENHANCED MICROBIOTA IMPACT | CONOPCO, INC., D/B/A UNILEVER (US) | 2026-05-14 | — | — | US | disclosed |
| US-12622861-B2 | Stable wash composition | CONOPCO, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20140256830-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | UNILEVER N.V. (NL) | 2014-09-11 | — | — | US | disclosed |
| US-20140256830-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | UNILEVER N.V. (NL) | 2014-09-11 | — | — | US | disclosed |
| US-20140256830-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | UNILEVER N.V. (NL) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622861-B2 | Stable wash composition | ALG1, IL4, CUTA | GPR55 1832/4885CNR2 2366/4885CNR1 1878/4885 |
| US-20140256830-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | NQO1, RBP4, KEAP1 | GPR55 3560/4885CNR2 4817/4885CNR1 4801/4885 |
| US-20260132356-A1 | MILD WASH COMPOSITION WITH BIODEGRADABLE THICKENER AND ENHANCED MICROBIOTA IMPACT | WASHC4, MUC1, WASHC5 | GPR55 1041/4885CNR2 2470/4885CNR1 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.